Rushton et al. further analyzed missense mutations affecting MS4A1 and registered a correlation between rapid DLBCL recurrence and reduced CD20 expression and stability following Rituximab administration, suggesting that previous anti-CD20 therapeutic regimens could affect CD20 × CD3 BsAbs’ efficacy [100]. Here, MS4A1 is linked to diffuse large B-cell lymphoma.